Immix Biopharma Inc
immixbio.comImmix Biopharma Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company that develops drug candidates for regulatory approval and eventual commercialization. The company generates no product revenue as of the fiscal year ended December 31, 2025, operating entirely on capital raises to fund clinical trials and research and development activities. Immix has incurred substantial losses since inception and disclosed in its 10-K filed March 25, 2026 that it anticipates continuing to incur substantial and increasing losses for the foreseeable future. The company relies on equity issuances, including at-the-market offerings and warrant instruments, to fund operations. An At The Market Offering Agreement with Citi was dated June 3, 2025. Audited by Crowe LLP (PCAOB ID#173) in Los Angeles, California, with a fiscal year ending December 31, 2025.
Products & Services
Clinical-stage drug candidates in development. Specific product names, indications, or pipeline stages are not supported by the provided filing excerpts.
Revenue Model
No product revenue disclosed in the filing excerpts. Operations are funded through equity capital raises, including common stock issuances and warrant instruments. The company has an At The Market Offering Agreement dated June 3, 2025.
Customers & Markets
No commercial customers disclosed. End markets are not specified in the provided filing excerpts. The company targets regulatory approval before any commercialization.
Geographic Exposure
Incorporated in the United States. Clinical and regulatory activities subject to FDA oversight and, based on data-privacy disclosures, potential operations or data handling subject to EU GDPR and California CCPA requirements.
Financial Snapshot
Loading...
